PCSK9 and polycystic ovary syndrome: Wang et al. [120] showed that PCSK9 inhibition by alirocumab partly improved lipid profiles and the morphology and function of the ovary in PCOS mice, including dysfunctions associated with endocrine function, follicular growth, and ovulation [112].